Fresenius lifts 2026 outlook after Q3 beat

Fresenius (FREd) lifted its 2026 guidance for the second time this year after third-quarter results came in ahead of expectations. The group now expects constant-currency core earnings per share growth at the upper end of its 10%-15% forecast range and is targeting an EBIT margin above 11.5%. These upgraded ambitions build on better-than-anticipated profitability and confirm management’s focus on improving margins and earnings through its main operating divisions.

Alongside the higher 2026 earnings targets, Fresenius maintained its forecast for group organic revenue growth of 4%-7%. The company is aiming to combine steady top-line expansion with improved profitability, reflected in the new margin objective. The latest outlook underscores management’s confidence that current operating trends can be sustained into the medium term.

In the third quarter, group EBIT before special items increased 10% in constant currency to €638 million, exceeding the €618.5 million expected by analysts. The group EBIT margin expanded by 50 basis points to 11%, illustrating operating leverage from revenue growth and efficiency measures. Core earnings per share rose 14% in constant currency to €0.72, ahead of the €0.69 market consensus.

Revenue performance also contributed to the guidance upgrade. Group revenue rose 5% organically to €5.80 billion, slightly above the €5.79 billion anticipated by analysts. While organic growth was below consensus percentage expectations, the combination of revenue growth and margin expansion delivered a stronger profit outcome than the market had projected.

Fresenius Kabi, which focuses on medicines and nutrition products, posted 6% organic revenue growth to €2.30 billion in the quarter. EBIT at Kabi increased 8% in constant currency to €391 million, giving the division an EBIT margin of 17%. Within Kabi, the growth vectors of biopharma, MedTech and nutrition achieved 9% organic revenue growth, highlighting their role in the group’s earnings momentum.

Biopharma revenue at Kabi rose 29% organically to €296 million, while MedTech revenue increased 6% to €428 million and nutrition revenue grew 4% to €646 million. Fresenius Kabi continues to expect organic revenue growth in the mid- to high-single-digit percentage range and anticipates an EBIT margin at the upper end of its 16.5%-17% forecast range, signaling ongoing emphasis on profitable growth.

Fresenius Helios, the hospital operator, also contributed significantly to the stronger quarter. Helios revenue increased 5% organically to €3.41 billion, while EBIT rose 19% in constant currency to €293 million. The division’s EBIT margin expanded to 8.6%, reflecting improved profitability in its core markets.

In Germany, Helios revenue advanced 5% organically to €2.10 billion, with EBIT up 25% to €202 million. In Spain, revenue grew 5% organically to €1.31 billion and EBIT rose 10% in constant currency to €92 million. Looking ahead, Helios expects organic revenue growth in the mid-single-digit percentage range and an EBIT margin between 10% and 10.5%, aligning divisional targets with the group’s higher profitability ambitions.

Fresenius’ financial profile showed further improvement alongside the earnings gains. Net debt to EBITDA stood at 2.5 times, indicating progress in reducing leverage while investing in growth areas such as biopharma and MedTech. The combination of higher profitability, controlled debt levels and reaffirmed revenue growth targets supports the upgraded 2026 outlook.

The stronger Q3 performance and raised guidance mark continued progress under the company’s transformation and margin-improvement efforts. With Kabi and Helios delivering solid revenue and EBIT growth, Fresenius is positioning its portfolio around businesses that are demonstrating both scale and improving returns, underpinning its higher medium-term earnings targets.